{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:39Z","timestamp":1794255879481,"version":"4.9.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03717-x","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:41:31Z","timestamp":1785400891000},"page":"4993-4998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Typical AMD: A Vodcast Exploring the Clinical and Therapeutic Landscape of PCV"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-8033","authenticated-orcid":false,"given":"Junyeop","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3717_CR1","volume-title":"Polypoidal choroidal vasculopathy","author":"H Chawla","year":"2023","unstructured":"Chawla H, Blair K, Vohra V. Polypoidal choroidal vasculopathy. StatPearls Publishing; 2023."},{"issue":"7","key":"3717_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","volume":"66","author":"G Anantharaman","year":"2018","unstructured":"Anantharaman G, Sheth J, Bhende M, et al. Polypoidal choroidal vasculopathy: pearls in diagnosis and management. Indian J Ophthalmol. 2018;66(7):896\u2013908. https:\/\/doi.org\/10.4103\/ijo.IJO_1136_17.","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"3717_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","volume":"38","author":"CMG Cheung","year":"2024","unstructured":"Cheung CMG. Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management. Eye. 2024;38(4):659\u201367.","journal-title":"Eye"},{"issue":"1","key":"3717_CR4","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.apjo.2025.100144","volume":"14","author":"P Ruamviboonsuk","year":"2025","unstructured":"Ruamviboonsuk P, Ng DSC, Chaikitmongkol V, et al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS). Asia Pac J Ophthalmol. 2025;14(1):100144. https:\/\/doi.org\/10.1016\/j.apjo.2025.100144.","journal-title":"Asia Pac J Ophthalmol"},{"key":"3717_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OPTH.S385827","volume":"17","author":"P Sen","year":"2023","unstructured":"Sen P, Manayath G, Shroff D, Salloju V, Dhar P. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol. 2023;17:53\u201370. https:\/\/doi.org\/10.2147\/OPTH.S385827.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"3717_CR6","first-page":"979","volume":"65","author":"K-E Choi","year":"2024","unstructured":"Choi K-E, Yoon E, Lee YJ, Bae SH, Yun C. Imaging and clinical features of pulsatile polypoidal choroidal vasculopathy using optical coherence tomography and indocyanine green angiography. Invest Ophthalmol Vis Sci. 2024;65(7):979.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3717_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000548709","volume":"68","author":"C Zhang","year":"2025","unstructured":"Zhang C, Zhang W, Wang T, Wen L, Zhang J. Polypoidal choroidal vasculopathy: from clinicopathological and molecular perspectives. Ophthalmic Res. 2025;68(1):521\u201330.","journal-title":"Ophthalmic Res"},{"key":"3717_CR8","unstructured":"Silva R, Koh A. Neovascular Phenotypes: Polypoidal Choroidal Vasculopathy. 2017. Available from: https:\/\/amdbook.org\/content\/neovascular-phenotypes-polypoidal-choroidal-vasculopathy. Accessed June 2026."},{"issue":"2","key":"3717_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10792-020-01620-0","volume":"41","author":"Y Sahu","year":"2021","unstructured":"Sahu Y, Chaudhary N, Joshi M, Gandhi A. Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices. Int Ophthalmol. 2021;41(2):753\u201365. https:\/\/doi.org\/10.1007\/s10792-020-01620-0.","journal-title":"Int Ophthalmol"},{"key":"3717_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-026-04967-7","author":"S Kim","year":"2026","unstructured":"Kim S, Lee YE, Han YE, Lee J. Multimodal structure\u2013function mapping of retinal sensitivity loss in pachychoroid spectrum diseases. BMC Ophthalmol. 2026. https:\/\/doi.org\/10.1186\/s12886-026-04967-7. (Online ahead of print).","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"3717_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/jcm11061543","volume":"11","author":"J Lee","year":"2022","unstructured":"Lee J, Kim YN, Kim JG. Monthly alternating injections of aflibercept and bevacizumab for neovascular age-related macular degeneration. J Clin Med. 2022;11(6):1543.","journal-title":"J Clin Med"},{"issue":"7","key":"3717_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Lida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"3717_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443.","journal-title":"JAMA Ophthalmol"},{"key":"3717_CR14","unstructured":"Singh SR & Chhablani J. Decoding EVEREST II and PLANET. Retinal Physician. March 1, 2018."},{"issue":"12","key":"3717_CR15","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/s41433-020-0803-6","volume":"34","author":"KX Cheong","year":"2020","unstructured":"Cheong KX, Grewal DS, Teo KYC, Gan ATL, Jaffe GJ, Cheung GCM. The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye. 2020;34(12):2257\u201363. https:\/\/doi.org\/10.1038\/s41433-020-0803-6.","journal-title":"Eye"},{"issue":"1","key":"3717_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.survophthal.2020.05.003","volume":"66","author":"KX Cheong","year":"2021","unstructured":"Cheong KX, Teo KYC, Cheung CMG. Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. Surv Ophthalmol. 2021;66(1):68\u201397. https:\/\/doi.org\/10.1016\/j.survophthal.2020.05.003.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"3717_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12886-023-03264-x","volume":"23","author":"J Lee","year":"2023","unstructured":"Lee J, Kim K, Kim ES, Yu SY, Kang MS. Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression. BMC Ophthalmol. 2023;23(1):511. https:\/\/doi.org\/10.1186\/s12886-023-03264-x.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"3717_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","volume":"36","author":"BJ Fenner","year":"2022","unstructured":"Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye. 2022;36(2):257\u201365. https:\/\/doi.org\/10.1038\/s41433-021-01688-7.","journal-title":"Eye"},{"issue":"6","key":"3717_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol. 2021;10(6):507\u201318. https:\/\/doi.org\/10.1097\/APO.0000000000000445.","journal-title":"Asia Pac J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:31Z","timestamp":1794254611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3717"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03717-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Junyeop Lee declares roles as a Consultant for Allergan plc (now AbbVie Inc.), AbbVie Inc., AMC Sciences Co. Ltd, Bayer AG, ILIAS Biologics, Inc., MabTics, Novartis AG, and Roche.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies. All referenced studies involving human participants were performed with appropriate ethical approval and in accordance with relevant ethical standards.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}